Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Boryung Biopharma Co., Ltd.

Clinicaltrial registered17 Nov 2026

Boryung Biopharma Co., Ltd.

17 Nov 2026: Trial registered · A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated Influenza. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
17 Nov 2026
Title
A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated Influenza
Conditions
Influenza
Phase
Phase 3
Study Type
Interventional
Status
Recruiting
Countries
South Korea
Country
South Korea
Reference
NCT07943390
Location
South Korea
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Boryung Biopharma Co., Ltd.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from South Korea

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.